Middle Coast Investing highlighted Zoetis Inc. in its second-quarter 2026 investor letter, citing stalled growth and intensifying competition as key factors behind the stock's recent performance. The investment advisor firm noted that the animal health company is struggling to maintain momentum as consumer inflation pressures force pet owners to reduce spending on premium treatments. This assessment comes as Zoetis shares have fallen significantly, trading at a substantial discount to their recent highs.
The firm described Zoetis, which Pfizer spun off in 2013, as a provider of pharmaceuticals, vaccines, and diagnostic products for both companion animals and livestock. According to Middle Coast Investing, the company's drugs address dermatological issues, parasites, worms, and pain. The advisor illustrated the product utility by noting that a shot of Portela, which blocks pain receptors triggered by arthritis, provides a three-month period of relief for a cat with foot arthritis resulting from a fall eight years prior.
Despite the fundamental description, the market has reacted negatively to the company's trajectory. On October 14, 2026, Zoetis closed at $75.29, valuing the firm at a $31.11 billion market capitalization. The stock has posted a 37.41% year-to-date pullback, with its price currently fluctuating within a 52-week range of $68.77 to $148.30. Middle Coast Investing attributed this decline to the company's struggle with competition amidst inflationary pressures, particularly in the United States where consumers are trading down from best-of-market treatments.
The broader market context provided in the letter indicates a challenging environment for investors. Middle Coast Investing reported that its U.S., Core U.S., and European portfolios returned -2.4%, -3.9%, and -5.0%, respectively, during the quarter. While these figures reflect headwinds, the underlying U.S. portfolio holdings generated median revenue growth of 7.2% and earnings growth of 16.4%. The firm stated that these fundamentals support a cautious strategy focused on resilient, well-capitalized businesses. Market breadth data for the period showed that S&P 500 stocks averaged a 9.7% return, with only 40.55% trading above their 200-day moving average.
Hedge fund sentiment toward Zoetis remains modest compared to other sectors. According to Insider Monkey's database, 64 hedge fund portfolios held Zoetis shares at the end of the second quarter, up from 57 in the previous quarter. However, the firm is not listed among the most popular stocks among hedge funds. Middle Coast Investing explicitly stated that while it acknowledges the potential of Zoetis as an investment, it believes certain AI stocks offer greater upside potential and carry less downside risk. The firm’s overall strategy emphasizes navigating a market where resilience is linked to AI spending amid higher rates and temporary energy security concerns driven by the U.S.-Iran conflict.